Targeted degradation of ⍺-synuclein aggregates in Parkinson's disease using the AUTOTAC technology.

"Declarations Ethics approval and consent to participateAll animal procedures were approved by Seoul National University and AUTOTAC Bio Inc. Institutional Animal Care and Use Committee (IACUC). Consent for publicationAll authors have approved the contents of this study and provided consent for publication. Competing interestsSeoul National University and AUTOTAC Bio Inc. have filed patent applications based on the results of this study. The remaining authors declare no competing interests. Competing interests Seoul National University and AUTOTAC Bio Inc. have filed patent applications based on the results of this study. The remaining authors declare no competing interests."

"Funding This work was supported by the National Research Foundation of Korea (NRF) grants funded by the Korea government (MIST) (NRF-2020R1A5A1019023 and NRF-2021R1A2B5B03002614 to Y.T.K). This work was also supported by Korea Drug Development Fund (KDDF) (RS-2022–00166787 to K.W.S)."